These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 33405424

  • 1. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M.
    Eur J Gastroenterol Hepatol; 2021 Oct 01; 33(10):1288-1297. PubMed ID: 33405424
    [Abstract] [Full Text] [Related]

  • 2. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ, Dutch Initiative on Crohn and Colitis (ICC).
    Aliment Pharmacol Ther; 2020 May 01; 51(9):880-888. PubMed ID: 32237087
    [Abstract] [Full Text] [Related]

  • 3. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.
    Dig Liver Dis; 2020 Mar 01; 52(3):268-273. PubMed ID: 31732444
    [Abstract] [Full Text] [Related]

  • 4. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, LEO [London, Exeter, Oxford] IBD Research Consortium .
    J Crohns Colitis; 2020 Oct 05; 14(10):1385-1393. PubMed ID: 32280965
    [Abstract] [Full Text] [Related]

  • 5. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M, Initiative on Crohn and Colitis.
    Clin Gastroenterol Hepatol; 2023 Jan 05; 21(1):182-191.e2. PubMed ID: 35644343
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
    Shin SH, Oh K, Hong SN, Lee J, Oh SJ, Kim ES, Na SY, Kang SB, Koh SJ, Bang KB, Jung SA, Jung SH, Kim KO, Park SH, Yang SK, Choi CH, Ye BD.
    Therap Adv Gastroenterol; 2023 Jan 05; 16():17562848231154103. PubMed ID: 36950251
    [Abstract] [Full Text] [Related]

  • 11. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S.
    World J Gastroenterol; 2024 Apr 07; 30(13):1871-1886. PubMed ID: 38659488
    [Abstract] [Full Text] [Related]

  • 12. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, Amiot A, Bouguen G.
    Aliment Pharmacol Ther; 2023 Mar 07; 57(6):676-688. PubMed ID: 36401585
    [Abstract] [Full Text] [Related]

  • 13. Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
    Vieujean S, Laharie D, Buisson A, Roblin X, Fumery M, Nancey S, Wils P, Altwegg R, Seidel L, Caron B, Peyrin-Biroulet L.
    Dig Liver Dis; 2024 Apr 07; 56(4):613-621. PubMed ID: 38065698
    [Abstract] [Full Text] [Related]

  • 14. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1707-1713. PubMed ID: 37843044
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
    Adimadhyam S, Lewis JD, Simon AL, Wolfe AE, Smith S, Hou L, Moyneur É, Reynolds JS, Toh S, Dobes A, Parlett L, Haynes K, Burris J, Dorand JE, Long MD, Kappelman MD.
    Inflamm Bowel Dis; 2024 Apr 03; 30(4):554-562. PubMed ID: 37358904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.